178 related articles for article (PubMed ID: 21084039)
1. Population pharmacokinetics of ustekinumab in patients with active psoriatic arthritis.
Zhu YW; Mendelsohn A; Pendley C; Davis HM; Zhou H
Int J Clin Pharmacol Ther; 2010 Dec; 48(12):830-46. PubMed ID: 21084039
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis.
Xu Z; Vu T; Lee H; Hu C; Ling J; Yan H; Baker D; Beutler A; Pendley C; Wagner C; Davis HM; Zhou H
J Clin Pharmacol; 2009 Sep; 49(9):1056-70. PubMed ID: 19617465
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity.
Xu ZH; Lee H; Vu T; Hu C; Yan H; Baker D; Hsu B; Pendley C; Wagner C; Davis HM; Zhou H
Int J Clin Pharmacol Ther; 2010 Sep; 48(9):596-607. PubMed ID: 20860913
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis.
Zhu Y; Hu C; Lu M; Liao S; Marini JC; Yohrling J; Yeilding N; Davis HM; Zhou H
J Clin Pharmacol; 2009 Feb; 49(2):162-75. PubMed ID: 19179295
[TBL] [Abstract][Full Text] [Related]
5. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.
Gottlieb A; Menter A; Mendelsohn A; Shen YK; Li S; Guzzo C; Fretzin S; Kunynetz R; Kavanaugh A
Lancet; 2009 Feb; 373(9664):633-40. PubMed ID: 19217154
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL-23, in Patients with Moderate to Severe Plaque Psoriasis.
Yao Z; Hu C; Zhu Y; Xu Z; Randazzo B; Wasfi Y; Chen Y; Sharma A; Zhou H
J Clin Pharmacol; 2018 May; 58(5):613-627. PubMed ID: 29341192
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.
McInnes IB; Kavanaugh A; Gottlieb AB; Puig L; Rahman P; Ritchlin C; Brodmerkel C; Li S; Wang Y; Mendelsohn AM; Doyle MK;
Lancet; 2013 Aug; 382(9894):780-9. PubMed ID: 23769296
[TBL] [Abstract][Full Text] [Related]
8. Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial.
Kavanaugh A; Menter A; Mendelsohn A; Shen YK; Lee S; Gottlieb AB
Curr Med Res Opin; 2010 Oct; 26(10):2385-92. PubMed ID: 20831455
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.
Narwal R; Roskos LK; Robbie GJ
Clin Pharmacokinet; 2013 Nov; 52(11):1017-27. PubMed ID: 23754736
[TBL] [Abstract][Full Text] [Related]
10. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
Zhou H; Mayer PR; Wajdula J; Fatenejad S
J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics of the TNF-α and IL-17A Dual-Variable Domain Antibody ABT-122 in Healthy Volunteers and Subjects With Psoriatic or Rheumatoid Arthritis: Analysis of Phase 1 and 2 Clinical Trials.
Khatri A; Othman AA
J Clin Pharmacol; 2018 Jun; 58(6):803-813. PubMed ID: 29364523
[TBL] [Abstract][Full Text] [Related]
12. Ustekinumab: a review of its use in psoriatic arthritis.
McKeage K
Drugs; 2014 Jun; 74(9):1029-39. PubMed ID: 24919864
[TBL] [Abstract][Full Text] [Related]
13. Treatment of psoriasis and psoriatic arthritis.
Papoutsaki M; Costanzo A
BioDrugs; 2013 Jan; 27 Suppl 1():3-12. PubMed ID: 23990277
[TBL] [Abstract][Full Text] [Related]
14. Confirmatory Population Pharmacokinetic Analysis for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin-6, in Patients With Moderately to Severely Active Rheumatoid Arthritis.
Xu Y; Hu C; Zhuang Y; Hsu B; Xu Z; Zhou H
J Clin Pharmacol; 2018 Jul; 58(7):939-951. PubMed ID: 29578578
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics analysis of guselkumab in healthy subjects and patients with psoriatic arthritis, plaque psoriasis and palmoplantar pustulosis.
Tran L; Yao Z; Xu Z; Vermeulen A
Br J Clin Pharmacol; 2022 Oct; 88(10):4481-4493. PubMed ID: 35470450
[TBL] [Abstract][Full Text] [Related]
16. Ustekinumab associated with flares of psoriatic arthritis.
Stamell EF; Kutner A; Viola K; Cohen SR
JAMA Dermatol; 2013 Dec; 149(12):1410-3. PubMed ID: 24132520
[TBL] [Abstract][Full Text] [Related]
17. Ustekinumab for the treatment of psoriasis and psoriatic arthritis: a drug evaluation and literature review.
Thibodaux RJ; Triche MW; Espinoza LR
Expert Opin Biol Ther; 2018 Jul; 18(7):821-827. PubMed ID: 29949399
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials.
Suleiman AA; Khatri A; Minocha M; Othman AA
Clin Pharmacokinet; 2019 Mar; 58(3):375-387. PubMed ID: 30123942
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease.
Adedokun OJ; Xu Z; Gasink C; Kowalski K; Sandborn WJ; Feagan B
Clin Ther; 2022 Oct; 44(10):1336-1355. PubMed ID: 36150926
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
Kawalec P; Holko P; Moćko P; Pilc A
Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
